213 related articles for article (PubMed ID: 8257443)
61. Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system.
Lamy S; Lafleur R; Bédard V; Moghrabi A; Barrette S; Gingras D; Béliveau R
J Cell Biochem; 2007 Jan; 100(1):100-11. PubMed ID: 16823770
[TBL] [Abstract][Full Text] [Related]
62. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1.
Higazi AA; Mazar A; Wang J; Reilly R; Henkin J; Kniss D; Cines D
Blood; 1996 May; 87(9):3545-9. PubMed ID: 8611676
[TBL] [Abstract][Full Text] [Related]
63. Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator.
Kindzelskii AL; Amhad I; Keller D; Zhou MJ; Haugland RP; Garni-Wagner BA; Gyetko MR; Todd RF; Petty HR
Histochem Cell Biol; 2004 Apr; 121(4):299-310. PubMed ID: 15042374
[TBL] [Abstract][Full Text] [Related]
64. Vitronectin binding to urokinase receptor in human breast cancer.
Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
[TBL] [Abstract][Full Text] [Related]
65. Integrin alphaMbeta2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils.
Pluskota E; Soloviev DA; Bdeir K; Cines DB; Plow EF
J Biol Chem; 2004 Apr; 279(17):18063-72. PubMed ID: 14769799
[TBL] [Abstract][Full Text] [Related]
66. Potential role of kringle-integrin interaction in plasmin and uPA actions (a hypothesis).
Takada Y
J Biomed Biotechnol; 2012; 2012():136302. PubMed ID: 23125522
[TBL] [Abstract][Full Text] [Related]
67. Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.
Kobayashi H; Ohi H; Shinohara H; Sugimura M; Fujii T; Terao T; Schmitt M; Goretzki L; Chucholowski N; Jänicke F
Br J Cancer; 1993 Mar; 67(3):537-44. PubMed ID: 8382511
[TBL] [Abstract][Full Text] [Related]
68. Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro.
Kobayashi H; Gotoh J; Hirashima Y; Fujie M; Sugino D; Terao T
J Biol Chem; 1995 Apr; 270(14):8361-6. PubMed ID: 7713945
[TBL] [Abstract][Full Text] [Related]
69. Regulation of the single-chain urokinase-urokinase receptor complex activity by plasminogen and fibrin: novel mechanism of fibrin specificity.
Higazi AA; Ajawi F; Akkawi S; Hess E; Kuo A; Cines DB
Blood; 2005 Feb; 105(3):1021-8. PubMed ID: 15353482
[TBL] [Abstract][Full Text] [Related]
70. Commentary on: 'Effect of purified soluble urokinase receptor on the plasminogen prourokinase activation system' by N. Behrendt and K. Dano, FEBS Letters, 393 (1996) 31-36.
Higazi AA
FEBS Lett; 1997 Feb; 402(2-3):291-2. PubMed ID: 9037212
[No Abstract] [Full Text] [Related]
71. Regulation of plasminogen activation by human U937 promonocytic cells.
Duval-Jobe C; Parmely MJ
J Biol Chem; 1994 Aug; 269(33):21353-7. PubMed ID: 8063761
[TBL] [Abstract][Full Text] [Related]
72. Thrombospondin forms complexes with single-chain and two-chain forms of urokinase.
Silverstein RL; Nachman RL; Pannell R; Gurewich V; Harpel PC
J Biol Chem; 1990 Jul; 265(19):11289-94. PubMed ID: 2141608
[TBL] [Abstract][Full Text] [Related]
73. The receptor for the plasminogen activator of urokinase type is up-regulated in transformed rat thyroid cells.
Ragno P; Cassano S; Degen J; Kessler C; Blasi F; Rossi G
FEBS Lett; 1992 Jul; 306(2-3):193-8. PubMed ID: 1321734
[TBL] [Abstract][Full Text] [Related]
74. Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Marutsuka K; Hasui Y; Asada Y; Naito S; Osada Y; Sumiyoshi A
Clin Exp Metastasis; 1995 Mar; 13(2):116-22. PubMed ID: 7882614
[TBL] [Abstract][Full Text] [Related]
75. Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.
Liu S; Bugge TH; Frankel AE; Leppla SH
Methods Mol Biol; 2009; 539():175-90. PubMed ID: 19377974
[TBL] [Abstract][Full Text] [Related]
76. Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Asano S; Seishima M; Kitajima Y
Clin Exp Dermatol; 2001 May; 26(3):289-95. PubMed ID: 11422178
[TBL] [Abstract][Full Text] [Related]
77. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours.
Casslén B; Gustavsson B; Astedt B
Eur J Cancer; 1991; 27(11):1445-8. PubMed ID: 1660294
[TBL] [Abstract][Full Text] [Related]
78. Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins.
Ranson M; Andronicos NM; O'Mullane MJ; Baker MS
Br J Cancer; 1998 May; 77(10):1586-97. PubMed ID: 9635833
[TBL] [Abstract][Full Text] [Related]
79. Induction of p53 by urokinase in lung epithelial cells.
Shetty S; Gyetko MR; Mazar AP
J Biol Chem; 2005 Jul; 280(30):28133-41. PubMed ID: 15937335
[TBL] [Abstract][Full Text] [Related]
80. The steady states and dynamics of urokinase-mediated plasmin activation.
Venkatraman L; Yu H; Bhowmick SS; Dewey F; Tucker-Kellogg L
Pac Symp Biocomput; 2010; ():190-200. PubMed ID: 19908371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
